Avacta Group plc

137 articles about Avacta Group plc

• LG Chem Life Sciences Expands Partnership with Avacta Group plc

  11/13/2019

  LG Chem selects second and third drug targets following rapid progress in first programme

• 

  BioSpace Global Roundup, Oct. 17

  10/17/2019

  Companies from across the globe provide business and pipeline updates.

• Avacta Group plc Enters Collaboration and Option Agreement With ADC Therapeutics

  10/10/2019

  As part of the multi-target collaboration Avacta will generate and optimise Affimer binders against three undisclosed cancer targets and provide these to ADC Therapeutics to target its proprietary cytotoxic warheads to the site of the tumour.

• 

  BioSpace Global Roundup, June 13

  6/13/2019

  Companies from across the globe share business and pipeline updates.

• Avacta Group plc Hits Clinical Candidate Selection Milestone for Affimer PD-L1 Inhibitor

  6/10/2019

  Selection of its first-time-in-human clinical candidate for the Affimer platform confirmed

• 

  BioSpace Global Roundup, June 6

  6/6/2019

  Companies from across the globe share updates on their pipelines and growth strategies.

• Avacta Group plc TMAC Programme Accelerates: Clinical Trial Planned for Early 2020

  6/3/2019

  Key linker element of Avacta’s novel TMAC™ drug conjugate to be tested in humans within 12 months

• Moderna exercises option for an exclusive product license with Avacta Group plc

  2/4/2019

  Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.

• 

  BioSpace Movers and Shakers: Dec. 17

  12/17/2018

  With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.

• Avacta Appoints Dr Jose Saro as Chief Medical Officer

  12/12/2018

  Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic

• Avacta and LG Chem Life Sciences Agree Multi-Target Affimer Therapeutics Development Alliance

  12/10/2018

  Avacta Group plc and LG Chem Life Sciences today announced a multi-target collaboration and development agreement.

• Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT Biotech

  5/22/2018

  Avacta Group plc is pleased to announce that its research collaboration with FIT Biotech Oy.

• Avacta and OncoSec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers

  1/22/2018

  The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology with the long-term aim of developing gene delivered Affimer immunotherapies.

• Avacta Group Plc Announces Positive Outcome of Proof-of-Concept Study With Glythera and Follow-on Drug Development Partnership

  1/15/2018

  Avacta Group plc is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully. 

• Avacta Group Initiates Gene Therapy Research Collaboration With FIT Biotech Oy

  10/9/2017

• FIT Biotech Initiates Gene Therapy Research Collaboration With Avacta Group

  10/6/2017

• Avacta Group Preliminary Results for the Year Ending 31 July 2017

  10/4/2017

• Avacta Group Establishes U.S. Business Development Team

  10/2/2017

• Avacta Group Demonstrates Key Performance Benefits Of Affimer Technology For Affinity Separation

  11/23/2016

• Avacta Group Release: Positive Results From First Preclinical In-Vivo Studies Of Affimer Therapeutics

  9/22/2016